Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Status:
Withdrawn
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of nivolumab and IRX-2 and how well they work in
treating participants with stage III-IVA oral cavity cancer or human papillomavirus
(HPV)-positive oropharyngeal cancer that can be removed by surgery. Monoclonal antibodies,
such as nivolumab, may interfere with the ability of tumor cells to grow and spread. IRX-2
may "turn on" the immune system and stimulate an immune response against tumor cells. Giving
nivolumab and IRX-2 followed by surgery may work better at treating oral cavity and
oropharyngeal cancer.